Rockemann M G, Seeling W, Duschek S, Reinelt H, Steffen P, Georgieff M
Department of Anesthesiology, University of Ulm, Germany.
Anesth Analg. 1997 Oct;85(4):864-9. doi: 10.1097/00000539-199710000-00028.
We compared the costs, quality of analgesia, and side effects of postoperative patient-controlled epidural analgesia (PCEA) with bupivacaine/sufentanil versus an epidural bolus (BOLUS) of clonidine/morphine in 68 patients with pancreatic surgery. Postoperative pain treatment was performed over 4 days: the PCEA pump was filled with bupivacaine 0.25% and sufentanil 2 micrograms/mL and set to 3-mL bolus and 10-min lockout time. BOLUS patients received injections of clonidine 150 micrograms plus morphine 2 mg on demand. Visual analog scale (VAS) score at rest and during coughing, heart rate (HR), systolic arterial pressure (SAP), incidence of postoperative nausea and vomiting, pruritus, duration of intestinal paralysis, hospital treatment, and costs for personnel and material were recorded. VAS scores during coughing (3 +/- 2.5 vs 5 +/- 3, P < 0.001) was higher, and HR (79 +/- 13 vs 89 +/- 15, P < 0.001), and SAP (110 +/- 18 vs 124 +/- 23, P < 0.001) were lower, in the BOLUS compared with the PCEA group. The incidence of hypotension (SAP < 80 mm Hg) was greater (6 vs 0, P < 0.001) in the BOLUS group. The incidence of all other side effects was comparable. The costs of personnel ($204 +/- $40 vs $166 +/- $38, P < 0.001) were higher in the BOLUS group, but the costs of material ($51 +/- $17 vs $87 +/- $18, P < 0.001) were higher in the PCEA group. Total costs ($62 +/- $9 vs $62 +/- $11 per day, P = 0.9) were comparable. We conclude that because of superior analgesia and reduced side effects at analogous costs, PCEA is preferable to the BOLUS technique for the treatment of postoperative pain.
An epidural clonidine/morphine bolus technique resulted in inferior analgesia, more side effects, and comparable costs compared with a bupivacaine/sufentanil patient-controlled regimen in a randomized controlled trial after abdominal surgery.
我们比较了68例胰腺手术患者术后使用布比卡因/舒芬太尼进行患者自控硬膜外镇痛(PCEA)与单次硬膜外注射可乐定/吗啡(BOLUS)的成本、镇痛质量和副作用。术后疼痛治疗持续4天:PCEA泵中填充0.25%布比卡因和2微克/毫升舒芬太尼,设置为3毫升单次推注和10分钟锁定时间。BOLUS组患者按需注射150微克可乐定加2毫克吗啡。记录静息和咳嗽时的视觉模拟量表(VAS)评分、心率(HR)、收缩压(SAP)、术后恶心呕吐发生率、瘙痒、肠麻痹持续时间、住院治疗情况以及人员和材料成本。与PCEA组相比,BOLUS组咳嗽时的VAS评分更高(3±2.5对5±3,P<0.001),而HR(79±13对89±15,P<0.001)和SAP(110±18对124±23,P<0.001)更低。BOLUS组低血压(SAP<80mmHg)发生率更高(6对0,P<0.001)。所有其他副作用的发生率相当。BOLUS组的人员成本更高(204±40美元对166±38美元,P<0.001),但PCEA组的材料成本更高(51±17美元对87±18美元,P<0.001)。总成本相当(每天62±9美元对62±11美元,P = 0.9)。我们得出结论,由于在类似成本下镇痛效果更好且副作用减少,PCEA在治疗术后疼痛方面优于BOLUS技术。
在腹部手术后的一项随机对照试验中,与布比卡因/舒芬太尼患者自控方案相比,单次硬膜外注射可乐定/吗啡技术导致镇痛效果较差、副作用更多且成本相当。